{"id":"https://openalex.org/W4379650281","doi":"https://doi.org/10.1158/1078-0432.c.6684414","title":"Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia","display_name":"Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia","publication_year":2023,"publication_date":"2023-06-07","ids":{"openalex":"https://openalex.org/W4379650281","doi":"https://doi.org/10.1158/1078-0432.c.6684414"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6684414","doi":"https://doi.org/10.1158/1078-0432.c.6684414","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6684414","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6684414","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026842309","display_name":"John Nathan Allan","orcid":"https://orcid.org/0000-0002-2088-0899","observed_orcids":["https://orcid.org/0000-0002-2088-0899"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John N. Allan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2088-0899","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian W. Flinn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6724-290X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005565037","display_name":"Tanya Siddiqi","orcid":"https://orcid.org/0000-0001-5292-8298","observed_orcids":["https://orcid.org/0000-0001-5292-8298"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tanya Siddiqi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5292-8298","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Ghia","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3750-7342","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034517642","display_name":"Constantine Si Lun Tam","orcid":"https://orcid.org/0000-0002-9759-5017","observed_orcids":["https://orcid.org/0000-0002-9759-5017"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Constantine S. Tam","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9759-5017","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0064-4549","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055100327","display_name":"Paul M. Barr","orcid":"https://orcid.org/0000-0002-9733-401X","observed_orcids":["https://orcid.org/0000-0002-9733-401X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul M. Barr","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9733-401X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078620979","display_name":"Anna Elinder Camburn","orcid":"https://orcid.org/0000-0002-6097-7839","observed_orcids":["https://orcid.org/0000-0002-6097-7839"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Elinder Camburn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6097-7839","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008054206","display_name":"Alessandra Tedeschi","orcid":"https://orcid.org/0000-0001-8724-2771","observed_orcids":["https://orcid.org/0000-0001-8724-2771"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alessandra Tedeschi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8724-2771","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085393928","display_name":"Xavier Camille Albert Badoux","orcid":"https://orcid.org/0000-0001-9042-527X","observed_orcids":["https://orcid.org/0000-0001-9042-527X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xavier C. Badoux","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9042-527X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035890812","display_name":"Ryan W. Jacobs","orcid":"https://orcid.org/0000-0001-7814-7959","observed_orcids":["https://orcid.org/0000-0001-7814-7959"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryan Jacobs","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7814-7959","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002467749","display_name":"Bryone Jean Kuss","orcid":"https://orcid.org/0000-0002-5811-1331","observed_orcids":["https://orcid.org/0000-0002-5811-1331"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bryone J. Kuss","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5811-1331","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013236194","display_name":"Livio Trentin","orcid":"https://orcid.org/0000-0003-1222-6149","observed_orcids":["https://orcid.org/0000-0003-1222-6149"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Livio Trentin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1222-6149","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053787554","display_name":"Cathy Zhou","orcid":"https://orcid.org/0000-0003-2406-1484","observed_orcids":["https://orcid.org/0000-0003-2406-1484"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cathy Zhou","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2406-1484","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109542836","display_name":"Anita Sz\u0151ke","orcid":"https://orcid.org/0000-0001-6975-7114","observed_orcids":["https://orcid.org/0000-0001-6975-7114"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita Szoke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6975-7114","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092111581","display_name":"Christopher Abbazio","orcid":"https://orcid.org/0000-0002-1917-7290","observed_orcids":["https://orcid.org/0000-0002-1917-7290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Abbazio","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1917-7290","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William G. Wierda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7357-270X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9909999966621399},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.9769999980926514},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":1.0},{"id":"https://openalex.org/keywords/fixed-duration-treatment","display_name":"fixed-duration treatment","score":0.6840000152587891},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7269999980926514},{"id":"https://openalex.org/keywords/17p-deletion","display_name":"17p deletion","score":0.9200000166893005},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":1.0},{"id":"https://openalex.org/keywords/unmutated-ighv","display_name":"unmutated IGHV","score":0.9869999885559082},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.9559999704360962},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8949999809265137},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7960000038146973},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8460000157356262},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.5899999737739563},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8650000095367432},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.44600000977516174}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8778316974639893},{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.8404625654220581},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.7669307589530945},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6307297945022583},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6150198578834534},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5305927991867065},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4869776666164398},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4826967716217041},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4748927652835846},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.45605748891830444},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.45105448365211487},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.2962178587913513},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2911548614501953}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.c.6684414","doi":"https://doi.org/10.1158/1078-0432.c.6684414","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6684414","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.c.6684414.v1","doi":"https://doi.org/10.1158/1078-0432.c.6684414.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6684414.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.c.6684414.v2","doi":"https://doi.org/10.1158/1078-0432.c.6684414.v2","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6684414.v2","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6684414","doi":"https://doi.org/10.1158/1078-0432.c.6684414","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6684414","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320333648","display_name":"Pharmacyclics","ror":"https://ror.org/03hm8w204"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1243376384","https://openalex.org/W1429374962","https://openalex.org/W2075875145","https://openalex.org/W2142099365","https://openalex.org/W2142741025","https://openalex.org/W2153923291","https://openalex.org/W2295348655","https://openalex.org/W2580821712","https://openalex.org/W2789078984","https://openalex.org/W3012733259","https://openalex.org/W3039488989","https://openalex.org/W3045571650","https://openalex.org/W3048790590","https://openalex.org/W3132537256","https://openalex.org/W3203683811","https://openalex.org/W4213453359","https://openalex.org/W4239531927","https://openalex.org/W4280503361","https://openalex.org/W4291320147"],"related_works":["https://openalex.org/W4379598412","https://openalex.org/W4385628205","https://openalex.org/W4282964256","https://openalex.org/W4400109298","https://openalex.org/W4401876857","https://openalex.org/W4379281324","https://openalex.org/W4379768976","https://openalex.org/W4206586970","https://openalex.org/W4380085383","https://openalex.org/W4213453359"],"abstract_inverted_index":{"AbstractPurpose:":[0],"The":[1],"CAPTIVATE":[2],"study":[3],"investigated":[4],"first-line":[5],"ibrutinib":[6,34,62,69,100,237],"plus":[7,35,70,101,238],"venetoclax":[8,36,71,102,239],"for":[9],"chronic":[10],"lymphocytic":[11],"leukemia":[12],"in":[13,37,52,242],"2":[14],"cohorts:":[15],"minimal":[16],"residual":[17],"disease":[18],"(MRD)-guided":[19],"randomized":[20,104],"discontinuation":[21],"(MRD":[22],"cohort)":[23],"and":[24,55,138,149,155,159,161,171,181,195,200,204,206,214,231,251],"Fixed":[25],"Duration":[26],"(FD":[27],"cohort).":[28],"We":[29],"report":[30],"outcomes":[31],"of":[32,61,68,99,114,132,224],"fixed-duration":[33,236],"patients":[38,79,90,110,136,243],"with":[39,91,111,137,175,235,244,248],"high-risk":[40,124,133,140,225,245,256],"genomic":[41,115,246],"features":[42,117],"[del(17p),":[43],"TP53":[44],"mutation,":[45],"and/or":[46],"unmutated":[47,182],"immunoglobulin":[48],"heavy":[49],"chain":[50],"(IGHV)]":[51],"CAPTIVATE.":[53],"Patients":[54,57],"Methods:":[56],"received":[58,83,103],"three":[59],"cycles":[60,67,98],"420":[63],"mg/day":[64],"then":[65],"12":[66,97],"(5-week":[72],"ramp-up":[73],"to":[74,253],"400":[75],"mg/day).":[76],"FD":[77],"cohort":[78,89],"(n":[80,178,187],"=":[81,179,188],"159)":[82],"no":[84],"further":[85],"treatment.":[86,106],"Forty-three":[87],"MRD":[88,94],"confirmed":[92],"undetectable":[93],"(uMRD)":[95],"after":[96],"placebo":[105],"Results:":[107],"Of":[108],"195":[109],"known":[112],"status":[113],"risk":[116],"at":[118],"baseline,":[119],"129":[120],"(66%)":[121],"had":[122],"\u22651":[123],"feature.":[125],"Overall":[126],"response":[127,144],"rates":[128,146,192,220],"were":[129,147,193,221],">95%":[130,222],"regardless":[131,223],"features.":[134,226,257],"In":[135,173],"without":[139,184,255],"features,":[141,247],"respectively,":[142,190],"complete":[143],"(CR)":[145],"61%":[148,162],"53%;":[150],"best":[151],"uMRD":[152,197],"rates:":[153,169,198,212],"88%":[154,170],"70%":[156],"(peripheral":[157,202],"blood)":[158,203],"72%":[160],"(bone":[163,208],"marrow);":[164,209],"36-month":[165,210],"progression-free":[166],"survival":[167,218],"(PFS)":[168],"92%.":[172],"subsets":[174],"del(17p)/TP53":[176,185],"mutation":[177,186],"29)":[180],"IGHV":[183],"100),":[189],"CR":[191],"52%":[194],"64%;":[196],"83%":[199],"90%":[201],"45%":[205],"80%":[207],"PFS":[211,233,250],"81%":[213],"90%.":[215],"Thirty-six\u2013month":[216],"overall":[217],"(OS)":[219],"Conclusions:":[227],"Deep,":[228],"durable":[229],"responses":[230],"sustained":[232],"seen":[234],"are":[240],"maintained":[241],"similar":[249],"OS":[252],"those":[254],"See":[258],"related":[259],"commentary":[260],"by":[261],"Rogers,":[262],"p.":[263],"2561":[264]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-06-08T00:00:00"}